Health Canada has approved Boey, Allergan Aesthetics' rapid-onset and short-duration neuromodulator, for the temporary improvement of glabellar lines. That single word — short-duration — is the whole story for injectors weighing how to expand a neurotoxin menu that has been built almost entirely on long-lasting products.

Boey targets the same indication Canadian practices know well: moderate-to-severe vertical frown lines between the brows, treated with injection into the corrugator and procerus muscles. What distinguishes this molecule is its kinetic profile. It kicks in faster than the incumbent toxins, and it wears off sooner. Health Canada's decision, reported by The Dermatology Digest, makes Allergan the first major aesthetics house to bring a deliberately short-acting neuromodulator to the Canadian market under a dedicated brand name.

Why does onset and duration matter?

Think through your consult room. Patients walk in wanting two different things, and until now one product had to serve both.

• The event-driven patient — a wedding, a reunion, a photoshoot — wants visible smoothing quickly, and doesn't necessarily want three to four months of effect afterward.
• The toxin-curious patient wants to trial the look before committing to a full-duration treatment.
• The expressives-adjacent patient may prefer a softer, shorter window of muscle quieting between standard cycles.

A rapid-onset, short-duration agent speaks directly to those segments. It also opens scheduling conversations practices haven't had: same-day results before an event, no waiting days for onset to become visible.

Allergan has not, in the material available, published the specific onset hours, duration weeks, dosing units, or trial effect sizes for Boey. Treat the approval as the confirmed fact and the clinical specifics as details to verify before counseling patients. The Dermatology Digest's report confirms the approval, the indication, and the brand positioning — nothing more. That constraint matters when a manufacturer's claims start circulating in marketing materials ahead of the monograph.

What does this change for Canadian practices?

Practically, three things. First, inventory: a second branded toxin from the AbbVie-owned aesthetics portfolio means clinics already stocking the franchise can consolidate ordering while offering differentiated duration. Second, consent conversations: patients need a clear explanation that this product trades longevity for speed, and that re-treatment intervals will be shorter if they want continuous effect. Shorter duration means more visits — and practices should be transparent that maintenance costs can stack up for patients who end up wanting the long-haul result.

Third, positioning. Boey will not replace the standard long-duration toxins for the majority of frown-line patients. It sits alongside them, and the practices that profit from it will be the ones who segment their patient file deliberately rather than defaulting to one vial for everyone.

Competitive read

The approval also signals where the category is heading. Neuromodulators have competed for years largely on potency, spread, and duration. Boey reframes the axis of competition toward temporal control — onset speed and reversibility of lifestyle fit. Expect competing manufacturers to answer, and expect patient expectations, shaped by that marketing, to arrive at your front desk before the detail visit does.

Canadian injectors should watch for the product monograph, training dates, and provincial reimbursement-irrelevant private-pay pricing — this is a cash-pay aesthetic, so pricing strategy will live entirely between clinic and supplier. When real-world onset and fade data accumulate across the first cohort of treated patients, the practical question will be whether the short-duration profile drives genuine new demand or simply cannibalizes existing toxin visits. The approval gives the market the tool; the next two quarters will show what it builds with it.